<--- Back to Details
First PageDocument Content
Epidemiology / Cancer organizations / Carcinogenesis / Epidemiology of cancer / Cancer / Joseph F. Fraumeni /  Jr. / National Institutes of Health / National Cancer Institute / Breast cancer / Medicine / Health / Oncology
Date: 2013-05-14 07:29:25
Epidemiology
Cancer organizations
Carcinogenesis
Epidemiology of cancer
Cancer
Joseph F. Fraumeni
Jr.
National Institutes of Health
National Cancer Institute
Breast cancer
Medicine
Health
Oncology

Linkage DCEG SENIOR ADVISORY GROUP RETREAT, 1999

Add to Reading List

Source URL: dceg.cancer.gov

Download Document from Source Website

File Size: 153,93 KB

Share Document on Facebook

Similar Documents

Journal of Machine Learning ResearchSubmitted 8/15; Revised 3/16; PublishedStructure-Leveraged Methods in Breast Cancer Risk Prediction

DocID: 1vq0d - View Document

Multicausality: Confounding - Assignment solutions 1. a. Reserpine is a risk factor. Overall, the incidence of breast cancer isper 100,000 women-years in reserpine users and 6.14 per 100,000 women-years in nonuser

DocID: 1vpNA - View Document

Frequently Asked Questions: Trainees seeking a PhD education in Cancer Biology or a related area with a focus on Breast Cancer Health Disparities. 1. What is the Komen Graduate Training in Disparities Research Grant (GT

DocID: 1voV1 - View Document

_____________________________________________________________ What to Do When Someone You Know Has Been Diagnosed with Breast Cancer [Last revised Mar 2014]

DocID: 1vlqg - View Document

Tangeretin inhibits the proliferation of human breast cancer cells via CYP1A1/CYP1B1 enzyme induction and CYP1A1/CYP1B1–mediated metabolism to the product 4′ hydroxy tangeretin

DocID: 1vl9e - View Document